Original Publication Date: 1 January, 2017
Publication / Source: Future Oncology
Authors: Demosthenes E Ziogas, John Spiliotis, Efstathios G Lykoudis, Georgios C Zografos & Dimitrios H Roukos
The recent evidence of spatiotemporal genomes and tumor evolution has led to the development of breakthrough next-generation sequencing (NGS) technologies. Intratumor heterogeneity (ITH) and circulating clonal diversity represent two of the most possible explanations of primary and secondary resistance. In this editorial, we discuss how extensive biobanking for each individual patient with subsequent genome sequencing can open novel horizons for precision medicine in breast cancer.